Lucentis (ranibizumab) 10 mg, 1 vial, Novartis Lucentis (ranibizumab) is used for approved retinal conditions including age-related macular degeneration. Medicine delivery from Europe with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.
Delivery methods
- Delivery of non-temperature-controlled medicines to Chisinau - $25.
Delivery of temperature-controlled medicines to Chisinau - $50.
Up to 5 packages can be sent per shipment. The price applies to one shipment. - Pickup from Odesafree
- Shipping within Ukraine by Nova Poshta at the carrier's rates.
Payment in UAH upon receipt of the order.
Delivery time
- Originator medicines: 5-7 days
- Generic medicines: 3-4 days
Payment methods
- Bank transfer to the settlement account after receiving the order
- Payment upon pickup in Odesa
Indications
- Treatment of neovascular (exudative) age-related macular degeneration (AMD).
- Treatment of visual impairment in diabetic macular edema (DMD).
- Treatment of visual impairment in macular edema caused by retinal vein thrombosis (central retinal vein thrombosis or central retinal vein thrombosis).
- Treatment of visual impairment due to choroidal neovascularization (CNN) secondary to pathological myopia (PM).
-
The recommended dose of Lucentis is 0,5 mg as a single intravitreal injection. This dose corresponds to an injection volume of 0,05 ml. The interval between injections of two doses in one eye should be at least 4 weeks.
Treatment should be started with one injection per month and continued until maximum visual acuity is achieved and/or signs of disease activity, i.e. changes in visual acuity and other disease symptoms, disappear. Patients with exudative AMD, AMD, and retinal vein thrombosis may initially require three or more consecutive monthly injections.
- Trade name:Lucentis
- Chemical name:Ranibizumab
- Dosage:10 mg
- Quantity:1
- Dosage form:Vial
No reviews yet
